Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer genetics

Cancer survives by silencing a gene


Breast cancer can become resistant to treatment by co-opting a gene-silencing mechanism, reports a team led by Steffi Oesterreich at the University of Pittsburgh in Pennsylvania.

The hormone oestrogen, which drives many breast cancers, dampens the activity of the tumour-fighting gene HOXC10, and drugs called aromatase inhibitors free the gene from this repression. But in a genome-wide screen of human breast-cancer cells, the team found that these drugs can also lead to a type of epigenetic modification called methylation — the addition of methyl groups to DNA without changing its sequence — across the genome. This ultimately silences HOXC10, rendering breast-cancer cells resistant to aromatase inhibitors.

Blocking the methylation activity associated with aromatase-inhibitor treatment might delay or prevent resistance to therapy, the authors say.

Sci. Transl. Med. 6, 229ra41 (2014)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cancer survives by silencing a gene. Nature 508, 11 (2014).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing